Form 4: GoodRx Director Douglas Hirsch Reports Stock Transactions

GoodRx director Douglas Hirsch reported the acquisition of deferred stock units and indirect holdings through grantor retained annuity trusts.

Summary

• Director Douglas Hirsch of GoodRx Holdings, Inc. reported a transaction on January 1, 2025.
• He acquired 6,392 deferred stock units, which will vest monthly starting January 31, 2025, and ending December 31, 2025.
• These units will settle upon specific events such as separation from service, change in control, death, or disability, or on December 31, 2028.
• Hirsch also has indirect ownership of 2,632,721 Class A common shares through the CH 2024-2 GRAT, where his spouse is the trustee, and another 2,632,721 shares through the DH 2024-2 GRAT, where he is the trustee.
• He disclaims beneficial ownership of the shares held by the CH 2024-2 GRAT.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not contain any information that would significantly impact sentiment. It is a neutral event.

Positives

• The acquisition of deferred stock units indicates continued alignment of the director's interests with the company's performance.
• The vesting schedule of the deferred stock units provides a long-term incentive for the director.

Risks

• The vesting of the deferred stock units is contingent on continued service, which could be a risk if the director were to leave the company.
• The indirect ownership through trusts adds complexity to the ownership structure.

Future Outlook

The deferred stock units will vest monthly until December 31, 2025, and will settle upon specific events or on December 31, 2028.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The use of grantor retained annuity trusts (GRATs) for estate planning is a common strategy among high-net-worth individuals, including corporate executives.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders, as it is a routine disclosure of a director's stock activity.

Key Dates

Keywords

GoodRx, Douglas Hirsch, deferred stock units, beneficial ownership, director, GRAT, stock transaction